Álvarez VM, Díaz MD, Rodríguez RR, Morier DL, Guzmán TMG

Idioma: Español
Referencias bibliográficas: 29
Paginas: 132-142
Archivo PDF: 182.99 Kb.

RESUMEN

Introducción: la inmunidad del hospedero desempeña un papel importante en determinar el desarrollo de las infecciones por dengue y del cuadro severo de la enfermedad. Sin embargo, otros factores intervienen en el complejo mecanismo de la patogénesis, como la variación entre las cepas virales.
Objetivos: evaluación de la capacidad neutralizante de un grupo de sueros de posconvalescientes frente a 2 cepas de dengue 4 pertenecientes a un mismo genotipo.
Métodos: se emplearon sueros de 68 individuos con un cuadro de fiebre del dengue y 35 con un cuadro clínico de fiebre hemorrágica del dengue.
Resultados: los títulos de anticuerpos neutralizantes en los sueros estudiados fueron bajos y se observó una capacidad neutralizante diferente entre las 2 cepas de dengue 4 del genotipo II. Se observaron diferencias significativas en los títulos de anticuerpos neutralizantes de los sueros procedentes de individuos con infección secundaria y con la forma severa de la enfermedad.
Conclusiones: estos resultados demuestran la complejidad de los anticuerpos neutralizantes, que se producen después de una infección por el virus dengue con diferentes cepas de un mismo serotipo, lo cual conduce a obtener resultados diversos por esta técnica que podría ser la causa de la trasmisión continuada de múltiples cepas de dengue.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Guzmán G, Kourí G. Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987-2007. Trans R Soc Trop Med Hyg. 2008;102:1-2.

2. Bernardo L, Fleitas O, Pavon A, Hermida L, Guillen G, Guzmán MG. Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes. Clin Vaccine Immunol. 2009 Dec;16(12):1829-31.

3. Falconar AK. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines. Clin Vaccine Immunol. 2008 Mar;15(3):549-61.

4. Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol. 2010;84:10630-43.

5. PAHO. Dengue and dengue hemorrhagic fever in the Americas: guidelines for prevention and control. Scientific publication no. 548. Washington: PAHO; 1994.

6. Rosario D, Álvarez M, Díaz J, Contreras R, Rodríguez R, Vázquez S, et al. Polymerase chain reaction for rapid detection and serotyping of dengue virus in clinical samples. Rev Panam Salud Publica. 1998 Jul;4(1):1-5.

7. Vázquez S, Pérez AB, Ruiz D, Rodríguez R, Pupo M, Calzada N, et al. Serological markers during dengue 3 primary and secondary infections. J Clin Virol. 2005 Jun;33(2):132-7.

8. Vázquez S, Acosta N, Ruiz D, Calzada N, Álvarez AM, Guzmán MG. Immunoglobulin G antibody response in children and adults with acute dengue 3 infection. J Virol Methods. 2009 Jul;159(1):6-9.

9. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol. 1985 Aug;22(2):250-4.

10. Álvarez M, Rodriguez-Roche R, Bernardo L, Morier L, Guzmán G. Improved Dengue virus plaque formation on BHK21 and LLCMK2 cells: Evaluation of Some Factors. Dengue Bull. 2005;29:49-57.

11. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol. 1967 Aug;99(2):285-90.

12. WHO. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. Geneva: Word Health Organization; 2007.

13. Gromowski GD, Barrett AD. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology. 2007 Sep 30;366(2):349-60.

14. Volk DE, Lee YC, Li X, Thiviyanathan V, Gromowski GD, Li L, et al. Solution structure of the envelope protein domain III of dengue-4 virus. Virology. 2007;364:147-54.

15. Gromowski GD, Barrett AD, Barrett ND. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol. 2008;82(17):8828-37.

16. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):48-60.

17. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg. 2002 Mar;66(3):264-72.

18. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):24-31.

19. Jin X, Block OT, Rose R, Schlesinger J. Dengue vaccine development and dengue viral neutralization and enhancement assays. Antivir Ther. 2009;14(6):739-49.

20. Chanthavanich P, Luxemburger C, Sirivichayakul C, Lapphra K, Pengsaa K, Yoksan S, et al. Short report: Immune response and occurrence of dengue infection in Thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Trop Med Hyg. 2006;75(1):26-8.

21. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. Am J Trop Med Hyg. 2009 Nov;81(5):825-33.

22. Álvarez M, Pavón-Oro A, Rodríguez-Roche R, Bernardo L, Morier L, Sánchez L, et al. Neutralizing antibody response variation against dengue 3 strains. J Med Virol. 2008 Oct;80(10):1783-9.

23. Hiramatsu K, Tadano M, Men R, Lai CJ. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology. 1996;224(2):437-45.

24. Lin B, Parrish CR, Murray JM, Wright PJ. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology. 1994;202(2):885-90.

25. Blaney JEJr., Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol. 2005 May;79(9):5516-28.

26. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis. 2004 Mar 15;189(6):990-1000.

27. Zulueta A, Martin J, Hermida L, Valdes I, Prado I. Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res. 2006(121):65-73.

28. Shresta S, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, King T, et al. The development of therapeutic antibodies that neutralize homologous and heterologous gemotypes of dengue virus type 1. PLoS Pathog. 2010;6:e1000823.

29. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol. 2010;84:9227-39.